SCHEMBL3001253

SCHEMBL3001253

Cc1cc(C)cc(-c2csc(N3CCC(S(=O)(=O)c4ccc(C(C)(C)C)cc4)CC3)n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 11/20 0.45
KMT2A Q03164 3/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
CYP1A2 P05177 1/20 0.45
POLB P06746 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 7/20 0.44
NPC1 O15118 6/20 0.44
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 1/20 0.40
USP2 O75604 1/20 0.38
RECQL P46063 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021694 0.91 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3014465 0.91 SMN1; SMN2 (0.55) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3009110 0.91 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3016386 0.90 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3015937 0.89 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3013667 0.89 SMN1; SMN2 (0.41) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3017057 0.88 SMN1; SMN2 (0.44) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3015361 0.88 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3016724 0.88 SMN1; SMN2 (0.54) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2
SCHEMBL3005986 0.88 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AALDH1A1MAPTCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885KMT2A 2680/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.